As part of the approval process of the Alka transaction, The Danish Competition and Consumer Authority has raised concerns about the transaction’s impact on the dynamics of the Danish insurance market. Tryg disagrees with the concerns, and has been in dialogue with the Authorities on ways to resolve the issues raised. Tryg has submitted non-structural remedies expected to resolve the concerns. The suggested remedies are now planned to be subject to a market test. The approval process has been prolonged in consequence and is expected to be finalised within the end of 2018.
Tryg expects the suggested remedies to resolve all concerns raised by the Authorities and remains confident on the positive effect of the Alka transaction on Tryg’s business going forward. Tryg confirms all previously stated financial targets including expected merger benefits from the Alka transaction of DKK 300m and the target of a technical result of DKK 3.3bn. in 2020.
Attachment
